These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. Our proprietary nanotechnology platform reformulates and delivers approved chemotherapy and widely-used radiotherapy to help people lead longer and healthier lives.Our transformative approach to targeting and eliminating recurrent tumors locally and precisely while reducing side effects systemically means more time in the sun.We strive to help patients spend less time in an infusion center receiving treatment and more time laughing, living, and sharing precious moments with friends and family.We are committed to developing breakthrough treatments that provide improved safety, efficacy, and convenience for patients battling rare cancers. After submitting your request, you will receive an activation email to the requested email address. AUSTIN, Texas, Feb. 06, 2020 (GLOBE NEWSWIRE) - Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), today announced that Greg B. Petersen has joined the Company’s Board of Directors to serve as an independent director, effective February 14, 2020. Our proprietary nanotechnology platform reformulates and delivers approved chemotherapy and widely-used radiotherapy to help people lead longer and healthier lives.Our transformative approach to targeting and eliminating recurrent tumors locally and precisely while reducing side effects systemically means more time in the sun.We strive to help patients spend less time in an infusion center receiving treatment and more time laughing, living, and sharing precious moments with friends and family.There are many reasons why we believe we possess the capacity and experience to develop and manufacture large-scale, sophisticated nanotechnology-encapsulated cytotoxic drugs that successfully meet patient needs around the globe:A fully GMP-compliant, validated, state-of-the-art, U.S. development and manufacturing facility supported by an ICH-compliant Quality Management System.A 10,000 square foot space with ISO Class 7 and 8 cleanrooms, including a negative pressure room for managing hazardous drugs.A dedicated analytical chemistry lab with multiple High Performance Liquid Chromatography (HPLC) systems with multiple detector capability, an environmental monitoring lab, and a fully qualified Water For Injection (WFI) system onsite. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the U.S. FDA does not accept the Company’s submission of a Phase 2 clinical trial protocol in Small Cell Lung Cancer patients with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy; the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA’s accelerated regulatory pathways; and the risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. By using this site, you agree to the use of cookies on your device for tracking and analytics. These cookies will be stored in your browser only with your consent. Plus Therapeutics, RNL, DocePLUS, DoxoPLUS, and ReSPECT are trademarks of Plus Therapeutics, Inc.Plus Therapeutics Announces Changes to its Board of DirectorsInvestor
A fully GMP-compliant, validated, state-of-the-art, U.S. development and manufacturing facility supported by an ICH-compliant Quality Management System. PLUS THERAPEUTICS, Inc. 4200 Marathon Blvd., Suite 200, Austin, TX 78756 USA Tel: +1.737.255.7194 ir@plustherapeutics.com
This category only includes cookies that ensures basic functionalities and security features of the website.
Plus Therapeutics, RNL, DocePLUS, DoxoPLUS, and ReSPECT are trademarks of Plus Therapeutics, Inc.This website uses cookies to improve your experience while you navigate through the website. AUSTIN, Texas, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: "We are happy that Greg Petersen has agreed to join our Board of Directors,” said Dr. Marc Hedrick, President and CEO of Plus Therapeutics. We are a publicly-traded company on Nasdaq (PSTV, an abbreviation of ‘POSITIVE’) with our headquarters in Austin, Texas and GMP-validated manufacturing facilities in San Antonio, Texas.